Aaron S. Kesselheim

1 month ago | yourlocalepidemiologist.substack.com | Katelyn K. Jetelina |Aaron S. Kesselheim

It’s outrageous how much we pay for brand-name drugs in the U.S. An EpiPen is $600 here and just $67 in the U.K. On Monday, the administration dropped an executive order to tackle drug costs. This issue is wildly confusing (sometimes I think that’s on purpose), but that doesn’t make it less important—drug prices shape the lives of millions of Americans. So, I partnered with Dr. Aaron S.

1 month ago | journals.plos.org | Kevin Rader |Shirley Wang |Aaron S. Kesselheim |Brandon J. Demkowicz

Loading metrics Open Access Peer-reviewedResearch Article Citation: Demkowicz BJ, Rader K, Wang SV, Kesselheim AS, Feldman WB (2025) The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study. PLoS Med 22(5): e1004596. https://doi.org/10.1371/journal.pmed.1004596Academic Editor: Alexander G.

2 months ago | washingtonpost.com | Peter Lurie |Aaron S. Kesselheim |Joshua M. Sharfstein

It’s not hard to see through RFK Jr.’s ‘radical transparency’ pledge (washingtonpost.com) It’s not hard to see through RFK Jr.’s ‘radical transparency’ pledge By Peter Lurie; Aaron Kesselheim; Joshua Sharfstein 2025042410300300 In his inaugural speech upon taking over as secretary of the Department of Health and Human Services, Robert F.

Dec 30, 2024 | bmj.com | William B. Feldman |Samy Suissa |Aaron S. Kesselheim |Jerry Avorn

Research BMJ 2024; 387 doi: https://doi.org/10.1136/bmj-2024-080409 Cite this as: BMJ 2024;387:e080409 Linked Editorial Environmentally friendly inhaler regimens for COPD William B Feldman, assistant professor1 2 3, Samy Suissa, professor4, Aaron S Kesselheim, professor1 3, Jerry Avorn, professor1 3, Massimiliano Russo, assistant professor5, Sebastian Schneeweiss, professor1 3, Shirley V Wang, associate professor1 3 1Division of Pharmacoepidemiology and Pharmacoeconomics, Department of...

Nov 25, 2024 | jamanetwork.com | Olivier J. Wouters |Matthew Vogel |William B. Feldman |Aaron S. Kesselheim

Differential Legal Protections for Biologics vs Small-Molecule Drugs in the US Abstract Importance  Biologics approved by the US Food and Drug Administration (FDA) receive 12 years of guaranteed protection from biosimilar competition compared with 5 years of protection from generic competition for new small-molecule drugs.